Position in OCGN
as of Mar 31, 2026
· filed Apr 13, 2026
Position Value
$64,367
+$13,550 QoQ
Shares Held
35,562
-30.6% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2021
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in OCGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026E Fund Management Co., Ltd. holds $74,284,596 across 116 Biotechnology names. OCGN ranks #106 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SMMT |
Summit Therapeutics Inc.
|
311,825 | $5,912,202 | |
| 2 | EVMN |
Evommune, Inc.
|
243,700 | $5,602,663 | |
| 3 | CELC |
Celcuity Inc.
|
46,337 | $5,288,905 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
10,816 | $4,829,776 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,825 | $3,727,988 | |
| 6 | IONS |
Ionis Pharmaceuticals Inc
|
46,688 | $3,505,801 | |
| 7 | KYMR |
Kymera Therapeutics, Inc.
|
26,231 | $2,184,779 | |
| 8 | AVBP |
ArriVent BioPharma, Inc.
|
93,953 | $2,167,495 |
All Filings in OCGN
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $64,367 | 35,562 | Shares | Sole | 2026-04-13 | |
| 2024-09-30 | $50,817 | 51,227 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $75,038 | 48,412 | Shares | Sole | 2024-08-12 | |
| 2022-12-31 | $168,347 | 129,498 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $236,629 | 132,938 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $360,666 | 158,884 | Shares | Sole | 2022-08-15 | |
| 2022-03-31 | $361,310 | 109,488 | Shares | Sole | 2022-05-12 | |
| 2021-12-31 | $146,755 | 32,254 | Shares | Sole | 2022-02-11 | |
| 2021-09-30 | $173,102 | 24,109 | Shares | Sole | 2021-11-12 | |
| 2021-03-31 | $94,150 | 13,866 | Shares | Sole | 2021-05-13 | |
| No filing history on record for this holder in this stock. | ||||||